home / stock / ifrx / ifrx news

IFRX News and Press, InflaRx N.V. From 04/30/24

Stock Information
Company Name: InflaRx N.V.
Stock Symbol: IFRX
Market: NASDAQ
Website: inflarx.de
Menu
IFRX IFRX Quote IFRX Short IFRX News IFRX Articles IFRX Message Board
Get IFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
IFRX - InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, befor...
IFRX - InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...

IFRX - InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (C...

IFRX - InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to...
IFRX - InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients. ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharm...

IFRX - InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing period Achieved ...

IFRX - 24/7 Market News Lunch Break 3 Nov 2023

2023-11-03 12:14:31 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (...
IFRX - 24/7 Market News Snapshot 3 Nov 2023

2023-11-03 09:53:11 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (NASDAQ: TNO...

IFRX - IFRX, LIXT and IOAC are among pre market gainers

2023-11-03 08:18:52 ET Werewolf Therapeutics  ( HOWL ) +38% jumps on early-sage data from lead program. DigitalOcean Holdings  ( DOCN ) +23% stock jumps 20%, guides Q4 and FY figures above consensus. InflaRx ( IFRX ) +16% . Block ( SQ ) +1...

IFRX - Expected earnings - InflaRx N.V.

InflaRx N.V. (IFRX) is expected to report $-0.29 for Q3 2023
Previous 10 Next 10